YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
* Arbutus Biopharma (ABUS [https://seekingalpha.com/symbol/ABUS]) traded higher on Wednesday after the antimicrobial drug developer announced plans to repurchase 46M shares of its common stock at $5 each as part of a previously disclosed t…
Should you bet on an established giant or a pipeline-driven innovator? This comparison examines Amgen (NASDAQ:AMGN) and Moderna (NASDAQ:MRNA) to see which stock is a better buy today. Amgen is a veteran in the drug manufacturing world, foc…
Healthcare stocks were higher Friday afternoon, with the NYSE Healthcare Index rising 1.4% and the S PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
* Arbutus Biopharma (ABUS [https://seekingalpha.com/symbol/ABUS]) said [https://seekingalpha.com/pr/20626537-arbutus-announces-intent-to-repurchase-up-to-us-230-million-of-its-common-shares-through] it plans to launch a modified Dutch auct…
Arbutus Biopharma Corporation WARMINSTER, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease, today ann…
Quick Read Moderna's 177% stock surge to a ~$70B market cap makes ABUS a prime target, as buying it eliminates $1.3B in LNP patent exposure. NTLA's Phase 3 lonvo-z showed 87% fewer hereditary angioedema attacks, while EDIT offers cardiomet…
Arbutus Biopharma Corporation Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026 Received first payment of approximately $178M from Moderna settlement in July and expect…
A landmark legal settlement in the biotech sector recently reshaped the financial trajectories of two key mRNA technology players: Arbutus Biopharma Corporation (NASDAQ:ABUS) and Moderna, Inc. (NASDAQ:MRNA). The resolution of their global…
Moderna MRNA reported a second-quarter 2026 loss of $1.97 per share, in line with the Zacks Consensus Estimate. The loss narrowed 7.5% from $2.13 a year ago. Total revenues in the second quarter were $145 million, which beat the Zacks Cons…
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Pfizer (PFE) is back in focus after Arbutus Biopharma and Genevant Sciences expanded their patent…
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Arbutus Biopharma and Genevant Sciences have filed multiple patent infringement lawsuits against Pfizer and BioNTech over th…
[Gavel on desk] CatLane Arbutus Biopharma (ABUS [https://seekingalpha.com/symbol/ABUS]) and Genevant Sciences, a subsidiary of Roivant Sciences (ROIV [https://seekingalpha.com/symbol/ROIV]), on Thursday announced the filing of three intern…
Arbutus Biopharma Corporation Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle ("LNP") technology against Pfizer and BioNTech Receive…
Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle (“LNP”) technology against Pfizer and BioNTech Received approximately $178M from Mod…
Key Points Moderna is evolving from a COVID-19 vaccine specialist into a multi-product firm with major oncology and rare disease partnerships. Recursion Pharmaceuticals is leveraging artificial intelligence and massive biological datasets…
As the biotechnology landscape shifts toward personalized medicine and advanced computing, investors are weighing established leaders against emerging tech-driven disruptors. Moderna (NASDAQ:MRNA) and Recursion Pharmaceuticals (NASDAQ:RXRX…
Arbutus Biopharma Corporation (NASDAQ:ABUS) is one of the 10 Most Profitable Small Cap Stocks to Buy. On May 13, 2026, Arbutus Biopharma Corporation (NASDAQ:ABUS) reported Q1 2026 revenue of $179.1 million with estimated license revenue ti…
* Arbutus Biopharma press release [https://seekingalpha.com/pr/20512977-arbutus-reports-first-quarter-2026-financial-results-and-provides-corporate-update] (ABUS [https://seekingalpha.com/symbol/ABUS]): Q1 GAAP EPS of $0.87. * Revenue of $…
Arbutus Biopharma Corporation Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities of $95…
Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation settlement with Moderna Strong financial position with cash, cash equivalents and marketable securities of $95.2M as of March 31, 2026 FDA g…
Moderna MRNA kicked off 2026 with encouraging first-quarter results, beating estimates for earnings and sales. The company’s total revenues surged 260% year over year to $389 million. Nearly 80% of this figure was generated from internatio…
For Immediate Release Chicago, IL – May 4, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial marke…
Moderna MRNA incurred an adjusted loss (excluding litigation settlement expenses) of $1.18 per share in the first quarter of 2026. In the year-ago period, the company reported a loss of $2.52. The Zacks Consensus Estimate was pegged at a l…
Moderna defied expectations of a Covid-revenue slowdown on Friday as a surge in international vaccine sales underpinned its first-quarter results. Revenue more than tripled in Moderna’s latest quarter to $389 million from $108 million last…
Arbutus Biopharma Corporation (NASDAQ:ABUS) is one of the best biotech penny stocks to buy in 2026. On March 23, Arbutus Biopharma concluded 2025 in a robust financial position, reporting $91.5 million in cash, cash equivalents, and market…
Arbutus Biopharma Corporation (NASDAQ:ABUS) is one of the 10 Best Penny Stocks to Buy and Hold Under $5. On April 14, 2026, Arbutus Biopharma Corporation (NASDAQ:ABUS) announced that the FDA granted Fast Track designation to imdusiran for…
Valued at a market cap of $21.2 billion, Moderna, Inc. (MRNA) is a biotechnology company that pioneered the use of messenger RNA (mRNA) therapeutics and vaccines to transform how medicines are created. The Cambridge, Massachusetts-based co…
We recently compiled a list of the 10 Best Biotech Stocks Under $10 to Buy. Arbutus Biopharma Corporation is among the best biotech stocks under $10 to buy. TheFly reported on April 7 that Jefferies lowered its price target on ABUS from $7…
* Arbutus Biopharma press release [https://seekingalpha.com/pr/20446883-arbutus-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-corporate] (ABUS [https://seekingalpha.com/symbol/ABUS]): Q4 GAAP EPS of -$0.17 misses…
Arbutus Biopharma Corporation Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025 $2.25B Moderna global settlement for infringement of lipid nanoparticle (LNP) delivery technology r…
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Moderna (NasdaqGS:MRNA) has reached a global settlement with Genevant Sciences and Arbutus Biopha…
Moderna Inc. (NASDAQ:MRNA) is one of the 10 Stocks Dominating Today's Market Action. Moderna snapped a two-day losing streak on Wednesday, jumping 15.99 percent to finish at $57.80 apiece after resolving a four-year legal dispute with two…
In early March 2026, Genevant Sciences and Arbutus Biopharma said they had reached a US$2.25 billion global settlement with Moderna over its past unauthorized use of their lipid nanoparticle delivery technology in COVID-19 vaccines, with M…
What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 17.4% in the afternoon session after the company settled a long-running patent dispute over the technology used in its COVID-19 vaccine. Moderna agreed to pay Arbu…
Moderna shares surged 16% Wednesday to their highest level since 2024 after the company agreed to pay up to $2.25 billion to two other biotechnology companies to settle patent litigation over its Covid-19 vaccine. Despite the expense, anal…
Moderna settled a yearslong patent dispute with Arbutus Biopharma and Roivant. Moderna stock jumped Wednesday. Continue Reading